Cellectar opens manufacturing facility for radiolabeled CLR1404
MRI has outrun other modalities in a screening trial involving high-risk women. Such research helps justify an estimated $1.4 billion a year in direct costs for the United States if new American Cancer Society guidelines
Breast MRI identifies mammographically occult secondary tumors in about 6% of women with early-stage breast cancer who would otherwise qualify for partial breast irradiation
Merck and Idera to develop TLR9 agonists for treatment of cancer
A cutting-edge prognostic tool called MammaPrint, developed by Agendia, a laboratory located in The Netherlands, uses molecular technology to predict whether breast cancer will metastasize, helping clinicians make more accurate management decisions for their patients.
Positron emission tomography (PET) can be used to better characterize patterns of local failure after definitive radiation therapy for non-small-cell lung cancer, which may help to improve that therapy
Use of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy to treat resected early-stage breast cancer is associated with good early outcomes in terms of local control, adverse effects, and cosmesis
The high cost of implementing new technologies has slowed the adoption rate of health information technologies, especially among smaller oncology practices. Based in Rockville, Maryland, Argole Systems, Inc. is a software and services company that recently released the beta version of Akessa Oncology, its new oncology-specific practice management and EMR system. Cancer Care & Economics spoke with Argole president, CEO, and co-founder Masoud Khorsand, MD.
10 notable developments and events in cancer research and care
Buoyed by effective postprocessing techniques, modern multislice CT has swept away some of the modality's limitations in visualizing the complex pancreas and created new challenges for radiologists in assessing incidentally detected lesions